NCT03228498View on ClinicalTrials.gov

Choline Alphoscerate-Nimodipine in Vascular Cognitive Impairment

PHASE2CompletedINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

May 2, 2017

Primary Completion Date

July 9, 2019

Study Completion Date

July 9, 2019

Conditions
Vascular Cognitive Impairment
Interventions
DRUG

Choline alphoscerate

Choline alphoscerate 600 mg b.i.d plus Nimodipine 30 mg t.i.d

DRUG

Placebo

Placebo b.i.d plus Nimodipine 30 mg t.i.d

Trial Locations (1)

50134

Stroke Unit, VAS-COG clinic, Azienda Ospedaliero Universitaria Careggi, Florence

All Listed Sponsors
collaborator

MDM S.p.A.

OTHER

lead

Azienda Ospedaliero-Universitaria Careggi

OTHER

NCT03228498 - Choline Alphoscerate-Nimodipine in Vascular Cognitive Impairment | Biotech Hunter | Biotech Hunter